GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AG-1343 | AG1343 | Viracept®
nelfinavir is an approved drug (FDA (1997))
Compound class:
Synthetic organic
Comment: Nelfinavir is an oral antiretroviral drug. It inhibits human immunodeficiency virus (HIV) protease.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Nelfinavir is used to treat HIV infection, usually in combination with other antiretroviral drugs. EMA marketing authorisation (granted in 1998) was later withdrawn. Nelfinavir has anti-cancer activity and radiosensitizing effects and has advanced to clinical trials for solid tumours and hematological malignancies. It is also being repositioned for COVID-19, having demonstrated antiviral activity against SARS-CoV-2 [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03256916 | Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix | Phase 3 Interventional | Tata Memorial Hospital | ||
| NCT02188537 | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | Phase 2 Interventional | Swiss Group for Clinical Cancer Research | ||
External links ![]() |
|
For extended ADME data see the following: Drugs.com |